ArticleBMC cell biology2009
Using multiplexed regulation of luciferase activity and GFP translocation to screen for FOXO modulators.
Article in BMC cell biology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 48 citations in OpenAlex.
- Transcription factor FoxO1 regulates myoepithelial cell diversity and growth.Scientific reports · 2024Article
- Assessing the Activity of Transcription Factor FoxO1.Methods in molecular biology (Clifton, N.J.) · 2023Article
- mTORC2 Is the Major Second Layer Kinase Negatively Regulating FOXO3 Activity.Molecules (Basel, Switzerland) · 2022Article
- Screening Health-Promoting Compounds for Their Capacity to Induce the Activity of FOXO3.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022Article
- Production of Fucoxanthin fromMarine drugs · 2021Article
- Article
- Therapeutic strategies targeting FOXO transcription factors.Nature reviews. Drug discovery · 2021Review
- Article
- Rapid and Efficient Synthetic Assembly of Multiplex Luciferase Reporter Plasmids for the Simultaneous Monitoring of Up to Six Cellular Signaling Pathways.Current protocols in molecular biology · 2020Article
- The tumor suppressor FOXO3a mediates the response to EGFR inhibition in glioblastoma cells.Cellular oncology (Dordrecht, Netherlands) · 2019Article
- Discovery of a Novel, Isothiazolonaphthoquinone-Based Small Molecule Activator of FOXO Nuclear-Cytoplasmic Shuttling.PloS one · 2016Article
- Methylseleninic acid promotes antitumour effects via nuclear FOXO3a translocation through Akt inhibition.Pharmacological research · 2015Article
- Targeting nucleocytoplasmic transport in cancer therapy.Oncotarget · 2014Review
- Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases.Investigational new drugs · 2013Article
- Nuclear accumulation of β-catenin and forkhead box O3a in colon cancer: Dangerous liaison.World journal of biological chemistry · 2012Article
- Deciphering the role of forkhead transcription factors in cancer therapy.Current drug targets · 2011Review
- Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells.Oncogene · 2010Article
- Insights to transcriptional networks by using high throughput RNAi strategies.Briefings in functional genomics · 2010Review
- Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases.The Journal of biological chemistry · 2009Article
- Adding more content to screening: reactivation of FOXO as a therapeutic strategy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIndependent luciferase reporter assays and fluorescent translocation assays have been successfully used in drug discovery for several molecular targets. We developed U2transLUC, an assay system in which luciferase and fluorescent read-outs can be multiplexed to provide a powerful cell-based high content screening method.
resultsThe U2transLUC system is based on a stable cell line expressing a GFP-tagged FOXO transcription factor and a luciferase reporter gene under the control of human FOXO-responsive enhancers. The U2transLUC assay measures nuclear-cytoplasmic FOXO shuttling and FOXO-driven transcription, providing a means to analyze these two key features of FOXO regulation in the same experiment. We challenged the U2transLUC system with chemical probes with known biological activities and we were able to identify compounds with translocation and/or transactivation capacity.
conclusionCombining different biological read-outs in a single cell line offers significant advantages over conventional cell-based assays. The U2transLUC assay facilitates the maintenance and monitoring of homogeneous FOXO transcription factor expression and allows the reporter gene activity measured to be normalized with respect to cell viability. U2transLUC is suitable for high throughput screening and can identify small molecules that interfere with FOXO signaling at different levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.